Hunter Smith

Interim Chief Executive Officer and Chief Financial Officer

Hunter Smith was appointed to serve as interim Chief Executive Office in March 2020. He has been our Chief Financial Officer since August 2017, and during that time he led the company in an initial public offering that netted the Company $125 million, as well as two follow-on public offerings that netted approximately $346 million. As a member of the management team, Hunter has played a critical role in charting Rhythm’s corporate strategy and managing the company’s performance. He has 20 years’ experience in global finance and management roles across multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. He joined Rhythm from Celgene Corporation, where he served as Vice President, Finance and Chief Financial Officer of the Company’s Inflammation and Immunology Business Unit. In this role, Hunter provided finance leadership for the global launch of Otezla®, co-led the integration of Receptos, Inc. following its acquisition by Celgene, and led global business planning and analysis for commercial affiliates and clinical study activities in over 16 countries. Before joining Celgene, Hunter worked for fourteen years in roles of increasing responsibility at Bunge Limited, including Director of Investor Relations, Chief Financial Officer–Asia, Chief Risk Officer, Corporate Treasurer, and Chief Financial Officer of Bunge’s Sugar and Bioenergy Segment. He holds an MBA in Finance from NYU’s Stern School of Business and a BA in History, with honors, from Northwestern University. Hunter served as an Independent Director of Genessee & Wyoming Inc. and as a member of the Compensation Committee, until its acquisition by Brookfield Infrastructure Partners in December 2019.